Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Recruiting 13Completed 5Active not recruiting 5Terminated 4Not yet recruiting 2

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Plasma cell 1Gynecologic 1

Conditions

Melanoma 3Uveal Melanoma 1

Interventions

pembrolizumab 58Ipilimumab 53Cyclophosphamide 53Nivolumab 45aldesleukin 35Interleukin-2 26fludarabine phosphate 22fludarabine 21Vemurafenib 20Temozolomide 19Radiotherapy 19dabrafenib 15trametinib 12Radiosurgery 11CTLA-4 Antigen 11spartalizumab 10Filgrastim 10Dacarbazine 10cobimetinib 9binimetinib 9atezolizumab 9Biopsy 9poly ICLC 8Paclitaxel 8Antilymphocyte Serum 8encorafenib 7avelumab 7Rituximab 7Introns 7romidepsin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × relatlimab × Dermatologic × Clear all
NCT05002569 2026-01-08

RELATIVITY-098

Bristol-Myers Squibb

Phase 3 Terminated
1,093 enrolled 15 charts
Dermatologic

Melanoma

NCT04935229 2025-10-22

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

TriSalus Life Sciences, Inc.

Phase 1 Terminated
67 enrolled
Dermatologic

Uveal Melanoma

NCT03978611 2024-07-24

A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

Bristol-Myers Squibb

Phase 1 Terminated
11 enrolled
Dermatologic

Melanoma

NCT03724968 2021-04-20

Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression

Vanderbilt-Ingram Cancer Center

Phase 2 Terminated
2 enrolled 6 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡